Lee Woonghee, Song Gwonhwa, Bae Hyocheol
Institute of Animal Molecular Biotechnology, Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea.
Department of Oriental Medicinal Biotechnology, College of Life Sciences, Kyung Hee University, Yongin 17104, Korea.
Antioxidants (Basel). 2022 Sep 24;11(10):1893. doi: 10.3390/antiox11101893.
Recent studies have identified obesity as one of the world's most serious chronic disorders. Adipogenesis, in which preadipocytes are differentiated into mature adipocytes, has a decisive role in establishing the number of adipocytes and determining the lipid storage capacity of adipose tissue and fat mass in adults. Fat accumulation in obesity is implicated with elevated oxidative stress in adipocytes induced by reactive oxygen species (ROS). Adipogenesis regulation by inhibiting adipogenic differentiation and ROS production has been selected as the strategy to treat obesity. The conventional anti-obesity drugs allowed by the U.S. Food and Drug Administration have severe adverse effects. Therefore, various natural products have been developed as a solution for obesity, suppressing adipogenic differentiation. Fraxetin is a major component extracted from the stem barks of , with various bioactivities, including anti-inflammatory, anticancer, antioxidant, and antibacterial functions. However, the effect of fraxetin on adipogenesis is still not clearly understood. We studied the pharmacological functions of fraxetin in suppressing lipid accumulation and its underlying molecular mechanisms involving 3T3-L1 preadipocytes. Moreover, increased ROS production induced by a mixture of insulin, dexamethasone, and 3-isobutylmethylxanthine (MDI) in 3T3-L1 was attenuated by fraxetin during adipogenesis. These effects were regulated by mitogen-activated protein kinase (MAPK) signaling pathways. Therefore, our findings imply that fraxetin possesses inhibitory roles in adipogenesis and can be a potential anti-obesity drug.
最近的研究已将肥胖确定为世界上最严重的慢性疾病之一。脂肪生成过程中，前脂肪细胞分化为成熟脂肪细胞，这在确定脂肪细胞数量以及决定成人脂肪组织的脂质储存能力和脂肪量方面具有决定性作用。肥胖中的脂肪堆积与活性氧（ROS）诱导的脂肪细胞氧化应激升高有关。通过抑制脂肪生成分化和ROS产生来调节脂肪生成已被选为治疗肥胖的策略。美国食品药品监督管理局批准的传统抗肥胖药物有严重的副作用。因此，人们开发了各种天然产物作为治疗肥胖的解决方案，以抑制脂肪生成分化。秦皮素是从白蜡树茎皮中提取的主要成分，具有多种生物活性，包括抗炎、抗癌、抗氧化和抗菌功能。然而，秦皮素对脂肪生成的作用仍不清楚。我们研究了秦皮素在抑制脂质积累方面的药理作用及其涉及3T3-L1前脂肪细胞的潜在分子机制。此外，在脂肪生成过程中，秦皮素可减弱胰岛素、地塞米松和3-异丁基-1-甲基黄嘌呤（MDI）混合物在3T3-L1中诱导的ROS产生增加。这些作用受丝裂原活化蛋白激酶（MAPK）信号通路调节。因此，我们的研究结果表明秦皮素在脂肪生成中具有抑制作用，可能是一种潜在的抗肥胖药物。
